Business Context and Reporting Period
This Form 8-K Current Report was filed by MRI Interventions, Inc. (not Clearpoint Neuro, Inc.) on August 28, 2014. The report details corporate governance changes, specifically the resignation of a director and the election of a new director, effective September 3, 2014.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
- Director Resignation: Michael A. Pietrangelo resigned from the Board of Directors and the Audit Committee effective September 3, 2014. The resignation was voluntary to facilitate the appointment of a new director and was not due to any disagreement with the company.
- Director Election: Pascal E.R. Girin was elected to the Board of Directors effective September 3, 2014. Mr. Girin brings over two decades of medical technology management experience, most recently as Executive Vice President and COO of Wright Medical Technology, Inc.
Compensation, Outlook, and Risks
Compensatory Arrangements
- Outgoing Director (Mr. Pietrangelo): The Compensation Committee accelerated the vesting of two stock options (45,000 shares and 20,000 shares). The exercise period for these and other existing options (totaling 70,000 additional shares) was extended through September 3, 2016.
- Incoming Director (Mr. Girin):
- Annual retainer: $15,000.
- Meeting fees: $1,000 per in-person meeting; $500 per telephone meeting.
- Equity: An initial option to purchase 45,000 shares vesting over three years. Additionally, an option to purchase 20,000 shares will be granted annually following stockholder meetings.
Risks and Contingencies
The company entered into a standard indemnification agreement with Mr. Girin, covering legal expenses, judgments, and fines incurred during his service as a director. The filing states there are no related person transactions or family relationships between Mr. Girin and other directors or officers.
Investor Verification Checklist
- Verify the effective date of the board composition change (September 3, 2014).
- Confirm the total number of shares subject to accelerated vesting for the outgoing director (65,000 shares).
- Review the vesting schedule for the new director's initial 45,000-share option grant.
- Check the press release (Exhibit 99.1) for any additional strategic commentary regarding the new director's appointment.